Crisaborole

Class: Anti-inflammatory Agents, Miscellaneous
Chemical Name: Benzonitrile, 4-[(1,3-dihydro-1-hydroxy-2,1-benzoxaborol-5-yl)oxy]
Molecular Formula:₁₄H₁₀BNO₃
CAS Number: 906676-24-3
Brands: Eucrisa

Medically reviewed by Drugs.com on May 11, 2022. Written by ASHP.

Introduction

Anti-inflammatory agent; selective phosphodiesterase type 4 (PDE4) inhibitor.

Uses for Crisaborole

Atopic Dermatitis

Topical treatment of mild to moderate atopic dermatitis (eczema) in adults and children ≥2 years of age.

Crisaborole Dosage and Administration

Administration

Topical Administration

Apply topically as a 2% ointment.

For external use only. Do not administer orally, vaginally, or topically to the eye.

Apply evenly as a thin layer to affected areas of skin.

Wash hands after applying, unless hands are being treated.

Dosage

Pediatric Patients

Atopic Dermatitis

Topical

Children ≥2 years of age: Apply thin layer of 2% ointment to affected areas of skin twice daily.

Adults

Atopic Dermatitis

Topical

Apply thin layer of 2% ointment to affected areas of skin twice daily.

Special Populations

No special population dosage recommendations.

Cautions for Crisaborole

Contraindications

• Known hypersensitivity to crisaborole or any ingredient in the formulation.

Warnings/Precautions

Sensitivity Reactions

Hypersensitivity Reactions

Hypersensitivity reactions (e.g., urticaria) reported.

Suspect hypersensitivity if severe pruritus, swelling, and erythema occur at site of application or at distant site.

If signs and symptoms of hypersensitivity occur, discontinue immediately and initiate appropriate treatment.

Specific Populations

Pregnancy

Data are inadequate regarding use of topical crisaborole in pregnant women.

Adverse embryofetal effects not observed in animal studies using oral crisaborole.

Lactation

Not known whether systemically absorbed crisaborole is distributed into human milk, affects human milk production, or affects breast-fed infants.

Consider benefits of breast-feeding and importance of the drug to the woman; also consider potential adverse effects on the breast-fed infant from the drug or underlying maternal condition.

Pediatric Use

Safety and efficacy not established in children <2 years of age.

Geriatric Use

Insufficient experience in patients ≥65 year...